The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, a next-generation CAR T-cell therapy developed by Caribou Biosciences for patients with relapsed or refractory multiple myeloma.
In an early clinical trial, CB-011 showed strong results. Among 12 previously untreated patients, 92% responded to the therapy. About 75% achieved a complete response or better, and most had no detectable cancer cells after treatment. Across a larger group of 48 patients, the therapy was generally safe, with no cases of graft-versus-host disease or serious movement disorders. Common side effects, such as low white blood cell counts and cytokine release syndrome, were manageable.
CB-011 is designed as an “off-the-shelf” treatment, meaning it uses donor T-cells rather than a patient’s own cells. This approach aims to avoid long manufacturing delays seen with current CAR T therapies and could allow faster treatment for many patients who currently cannot access these therapies in time.
The RMAT designation is expected to speed up development and regulatory review. The company plans to release more trial data and work with the FDA on next steps in 2026.